Anjali Vaidya, MD, FACC, FASE, FACP, Director, Advanced Pulmonary Hypertension, Right Heart Failure & CTEPH Program at Temple University Hospital, offered insight to Healio on findings from the HYPERION trial, the long-awaited study of Sotatercept in pulmonary arterial hypertension (PAH) within one year after initial diagnosis. The findings were presented at the ERS Congress and simultaneously published in the New England Journal of Medicine. Dr. Vaidya was not involved in the trial.
Weather Alert: Following the winter storm, all Temple Health hospitals, campuses and clinical locations remain open, though some appointments or services may be adjusted. Patients will be contacted directly if their visit is affected. Please check TempleHealth.org or FoxChase.org for updates and monitor myTempleHealth for changes to scheduled appointments.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH